BCT vs. SVA, PDP, MBX, EMH, PMN, DMT, HBP, IBT, ACST, and AEZS
Should you be buying BriaCell Therapeutics stock or one of its competitors? The main competitors of BriaCell Therapeutics include Sernova (SVA), Pediapharm (PDP), Microbix Biosystems (MBX), Emerald Health Therapeutics (EMH), ProMIS Neurosciences (PMN), Small Pharma (DMT), Helix BioPharma (HBP), IBEX Technologies (IBT), Acasti Pharma (ACST), and Aeterna Zentaris (AEZS). These companies are all part of the "biotechnology" industry.
BriaCell Therapeutics vs.
Sernova (TSE:SVA) and BriaCell Therapeutics (TSE:BCT) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, institutional ownership, analyst recommendations, risk, community ranking, profitability, dividends, earnings and media sentiment.
Sernova received 10 more outperform votes than BriaCell Therapeutics when rated by MarketBeat users. However, 100.00% of users gave BriaCell Therapeutics an outperform vote while only 91.67% of users gave Sernova an outperform vote.
0.1% of Sernova shares are held by institutional investors. Comparatively, 15.0% of BriaCell Therapeutics shares are held by institutional investors. 12.1% of Sernova shares are held by insiders. Comparatively, 9.3% of BriaCell Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Sernova currently has a consensus target price of C$1.83, suggesting a potential upside of 840.17%. Given Sernova's stronger consensus rating and higher possible upside, analysts clearly believe Sernova is more favorable than BriaCell Therapeutics.
BriaCell Therapeutics' return on equity of -206.01% beat Sernova's return on equity.
Sernova is trading at a lower price-to-earnings ratio than BriaCell Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Sernova had 3 more articles in the media than BriaCell Therapeutics. MarketBeat recorded 3 mentions for Sernova and 0 mentions for BriaCell Therapeutics. BriaCell Therapeutics' average media sentiment score of 0.00 beat Sernova's score of -0.08 indicating that BriaCell Therapeutics is being referred to more favorably in the news media.
Sernova has a beta of 1.35, indicating that its share price is 35% more volatile than the S&P 500. Comparatively, BriaCell Therapeutics has a beta of 1.83, indicating that its share price is 83% more volatile than the S&P 500.
Summary
Sernova beats BriaCell Therapeutics on 9 of the 16 factors compared between the two stocks.
Get BriaCell Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for BCT and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
BriaCell Therapeutics Competitors List
Related Companies and Tools
This page (TSE:BCT) was last updated on 1/21/2025 by MarketBeat.com Staff
Free BCT Stock Alerts